PULMATRIX, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
PULMATRIX, INC. (PULM) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $36.54 per share for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2025-08-06
- PULMATRIX, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2019-03-31 was $0.00.
- PULMATRIX, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- PULMATRIX, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2017-03-31 was $2.19.
- PULMATRIX, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2016-03-31 was $0.00.
- PULMATRIX, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- PULMATRIX, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2017 was $2.19, a 28.07% increase from fiscal 2016.
- PULMATRIX, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2016 was $1.71, a 19.34% decline from fiscal 2015.
- PULMATRIX, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2015 was $2.12.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-06-30 | $36.54 10-Q · filed 2025-08-06 | |||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-05 | |||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-15 | |||
| 2018-12-31 | $0.00 10-K · filed 2019-02-19 | |||
| 2018-09-30 | $0.00 10-Q · filed 2018-11-14 | |||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-03 | |||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-11 | |||
| 2017-12-31 | $2.19 10-K · filed 2018-03-13 | |||
| 2017-09-30 | $2.19 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $2.19 10-Q · filed 2017-08-04 | |||
| 2017-03-31 | $2.19 10-Q · filed 2017-05-05 | |||
| 2016-12-31 | $1.71 10-K · filed 2017-03-10 | |||
| 2016-09-30 | $1.71 10-Q · filed 2016-11-04 | |||
| 2016-06-30 | $1.71 10-Q · filed 2016-08-04 | |||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-05 | |||
| 2015-12-31 | $2.12 10-K · filed 2016-03-10 | |||
| 2015-09-30 | $2.12 10-Q · filed 2015-11-12 | |||
| 2015-06-30 | $2.11 10-Q · filed 2015-08-14 | |||
| 2015-03-31 | $0.00 10-K · filed 2015-06-10 | |||
| 2014-12-31 | $0.00 10-Q · filed 2015-02-13 | |||
| 2014-09-30 | $0.00 10-Q · filed 2014-11-13 | |||
| 2014-06-30 | $0.00 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |